Clinical Trials Directory

Trials / Completed

CompletedNCT00203125

A Study to Evaluate the Effects of Tyramine in Patients Who Completed the PRESTO Study.

Sub-study to Evaluate the Effect of An Oral Dose of Tyramine in Subjects Completing 26 Weeks of Participation in PRESTO (TVP-1012/133)

Status
Completed
Phase
Phase 3
Study type
Interventional
Enrollment
55 (actual)
Sponsor
Teva Branded Pharmaceutical Products R&D, Inc. · Industry
Sex
All
Age
Healthy volunteers
Not accepted

Summary

This study is to determine if Tyramine has any side effects on patients receiving 0.5mg, 1mg of Rasagiline or Placebo

Conditions

Interventions

TypeNameDescription
DRUGrasagiline mesylate0.5 or 1 mg oral, once-daily
OTHERtyramine50 mg once daily

Timeline

Start date
2000-10-01
Primary completion
2003-01-01
Completion
2003-01-01
First posted
2005-09-20
Last updated
2011-04-12

Source: ClinicalTrials.gov record NCT00203125. Inclusion in this directory is not an endorsement.